1-Butan-2-ylpiperidin-2-one | 73195-89-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Butan-2-ylpiperidin-2-one
• CAS: 73195-89-8
• 化学式: C₉H₁₇NO
• 分子量: 155.24
• InChiKey: LXSGEEOQBAIROG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  哌啶酮 、 2-溴丁烷 、 四丁基溴化铵 、 氢氧化钾 以65%的产率得到
  参考文献：
  名称：

  TAKAHATA H.; HASHIZUME T.; YAMAZAKI T., HETEROCYCLES, 1979, 12, NO 11, 1449-1451

  摘要：

  DOI：

文献信息

• METHODS OF PREPARING FACTOR XA INHIBITORS AND SALTS THEREOF
  申请人：Pandey Anjali

  公开号：US20110152530A1

  公开（公告）日：2011-06-23

  The present invention provides for methods of preparing compounds of Formula I or a salt of the compound or a hydrate of the compound or salt thereof that are factor Xa inhibitors. Specifically the present invention provides a method of preparing the compound 5-chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-imidazol-4-yl)methyl)thiophene-2-carboxamide, or a salt of the compound or a hydrate of the compound or salt thereof.

  本发明提供了制备化合物I的方法，或者该化合物的盐或水合物，这些化合物是因子Xa抑制剂。具体地，本发明提供了一种制备化合物5-氯-N-((1-(4-(2-氧代吡啶-1(2H)-基)苯基)-1H-咪唑-4-基)甲基)噻吩-2-甲酰胺的方法，或者该化合物的盐或水合物，或者其盐的方法。
• FACTOR XA INHIBITORS
  申请人：Zhu Bing-Yan

  公开号：US20090298806A1

  公开（公告）日：2009-12-03

  The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

  本发明涉及由公式I表示的化合物及其药学上可接受的盐、溶剂化合物、水合物和前药，这些化合物是凝血因子Xa的抑制剂。本发明还涉及制备这些化合物所使用的中间体，含有这些化合物的药物组合物，预防或治疗一系列由不良血栓形成表征的疾病的方法，以及抑制血样的凝血的方法。
• CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
  申请人：Lanter James C.

  公开号：US20110312936A1

  公开（公告）日：2011-12-22

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 4 , J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

  本发明涉及I式化合物，其中：R1、R2、R4、J、Q和A如规范中所定义。本发明还涉及一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病是II型糖尿病、肥胖和哮喘。本发明还涉及通过给哺乳动物施加至少一种I式化合物的治疗有效量来抑制CCR2活性的方法。
• Polyene macrolide derivative
  申请人：Shionogi & Co., Ltd.

  公开号：US10246478B2

  公开（公告）日：2019-04-02

  The present invention is the following Amphotericin B derivative: wherein each symbol is defined in description. The compound of the present invention has 16th position (X) is urea structure, cyclic structure, hydroxyalkyl or substituted monoalkylcarbamoyl. The compound of the present invention has antifungal activity.

  本发明是以下两性霉素 B 衍生物： 其中各符号在说明中定义。本发明化合物的第 16 位（X）是脲结构、环状结构、羟烷基或取代的单烷基氨基甲酰基。本发明化合物具有抗真菌活性。
• Heteroaryl compounds as IRAK inhibitors and uses thereof
  申请人：Merck Patent GmbH

  公开号：US10392375B2

  公开（公告）日：2019-08-27

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.

  本发明涉及可用作 IRAK 抑制剂的式 I 化合物及其药学上可接受的组合物。